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ABSTRACT
The existing vaccines against influenza are based on 
the generation of neutralizing antibody primarily 
directed against surface protein, haemagglutinin 
(HA) and neuraminidase (NA). However, antigenic 
drift and occasional shift of these two membrane 
glycoproteins, HA and NA, make vaccine production 
cumbersome and necessitate yearly revision of 
the vaccine seed strains by the World Health 
Organization. For these reasons, many investigators 
have often tried to look at the possibility of generating 
a universal vaccine useful against more than one 
influenza strain. The objective of research was to 
obtain an alternative antigen as vaccine candidate 
for universal flu vaccination, instead of HA and NA 
components. In this study, we use conserved epitope 
M2e which is consist of three major component 
such as N-terminal M2e2-24 (24 amino acids),trans-
membrane (59 amino acids) and C-terminal (19 
amino acids). We design two components of antigen, 
linier and branched structures. The antigens then 
formulated with aluminium hydroxide gel compared 
to FCA/IFA adjuvant. These vaccines were tested 
their immunogenicity, and the potency to mature the 
dendritic cells for stimulating either CD8+ T cell or 
antibody-mediated immune responses. The antibody 
titre and the maturity of dendritic cell indicated by 
cytokines concentration such as; IFN-γ, IL2 and IL4 
were measured by ELISA test.The result of research 
showed that the conserved epitope of Me2 2-16 when 
incorporated with P25 protein from canine distemper 
virus (linear structure) in alhydrogel adjuvant has 
greater potential to produce anti-M2e antibodies 
than in Freund adjuvant.  Alhydrogel adjuvant had 
a stronger effect than Freund adjuvant. Alhydrogel 
also stimulate the release of IL-2 and IL-4.
Keywords: Epitopes, innate and adaptive immune 
responses, M2e-protein, haemagglutinin (HA), 
neuraminidase (NA), adjuvant.
ABSTRAK
Vaksin influenza yang ada saat ini dibuat berdasarkan 
atas protein permukaan virus hemaglutinin (HA) 
dan neuramidase (NA).akan tetapi, karena kedua 
membran glikoprotein HA dan NA ini mudah mutasi, 
secara drift dan shift, maka vaksin yang diproduksi 
harus selalu direvisi setiap tahun oleh Badan 
Kesehatan Dunia (WHO). Para peneliti berusaha 
mencari kemungkinan untuk membuat vaksin 
universal yang bisa digunakan terhadap berbagai 
strain virus influenza. Tujuan dari penelitian ini 
adalah untuk mencari antigen alternatif untuk 
kandidat vaksin influenza universal selain HA dan 
NA. Dalam studi ini, kami menggunakan epitope M2e 
lestari yang mempunyai tiga komponen utama, yaitu 
N-terminal M2e2-24 (24 asam amino), komponen 
transmembran (59 asam amino) dan C-terminal 
(19 asam amino). Kami mendesain dua komponen 
antigen, yaitu struktur linier dan bercabang. Kedua 
antigen tersebut kemudian diformulasi dengan 
adjuvant aluminium hidroksida gel, dibandingkan 
dengan adjuvant FCA dan IFA.Vaksin-vaksin ini 
kemudian diuji imunogenisitasnya dan kemampuan 
untuk mematangkan sel dendritik yang akan 
menstimulasi sel CD8+ T atau respon kekebalan 
yang dimediasi antibodi. Adanya titer antibodi dan 
kematangan sel dentritik ditunjukkan oleh adanya 
konentrasi sitokin seperti interferon gamma, IL-2 
dan IL-4 diukur dengan metode ELISA. Hasil 
penelitian menunjukkan bahwa epitope lestari M2e 
2-16 jika digabungkan dengan protein P25 dari 
CDV (struktur linier) Di dalam adjuvant alhidrogel 
mempunyai potensi yang besar dalam memproduksi 
antibody M2e dibandingkan dengan adjuvant 
Freund. Adjuvan alhidrogel mempunyai efek yang 
lebih besar dari pada adjuvant freund. Alhidrogel 
juga menstimulasi penegluaran sitokin IL-2 dan IL-
4.
Kata kunci: Epitop, respon imun bawaan dan adaptif, 
M2E-protein, hemaglutinin (HA), neura-
minidase (NA), adjuvant.
INTRODUCTION
The world history recorded six times pandemic 
flu caused by influenza A virus. The worst case 
pandemic flu happened in 1918 in Spain, fifty million 
people were killed.  WHO always monitored the 
movement of influenza A virus every year. The effort 
seemingly successful to control the situation, there 
is no pandemic flu  since 1977 until now. However, 
the mankind still worry as the epidemic influenza still 
happened in several  countries like Hongkong, and 
Mexico in 2009 and almost 50 countries has influenza 
H5N1 outbreak since 2000-2006. The worst case of 
influenza H5N1 infection during this period  was 
in Indonesia. The mortality rate  was 84% compare 
with the world mortality rate case which is only 46%. 
Vaccination was a turning point in the war between 
microbes and humans, vaccines represent the most 
cost-effective life-saving device in history. The 
failure to develop influenza vaccines against global 
pandemics will bring to a great disaster for humanity 
(WHO, 2012).
Research during the past decade has identified a 
fundamental role for the innate immune system in sensing 
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vaccines and adjuvants and in programming protective 
immune responses. The innate immune system can 
sense microbes through pattern-recognition receptors 
(PRRs), such as the Toll-like receptors (TLRs), which are 
expressed by various cells, including dendritic cells (DCs). 
In addition to TLRs, other types of PRRs, including the 
C-type lectin-like receptors and the cytosolic Nod-like 
receptors, sense a broad range of microbial stimuli, and 
the cytosolic RIG-I-like receptors sense viral nucleic 
acids (Reed et al., 2008). Dendritic cell (DCs) take up 
antigen, generate peptide epitopes from it, and then load 
these epitopes into molecules that are encoded by the 
major histocompatibility complex (MHC). After export 
to the cell surface, MHC molecule-epitope complexes are 
presented to T cell, leading to their activation. Activated 
CD4+ helper T (Th) cells are now able to deliver signals 
to DCs, enabling them to activate naïve CD8+ T cell more 
efficiently and also improve the CD8+ cell’s ability to 
assume memory cell status, providing the ability to clear 
pathogens when subsequently encountered. Activated Th 
cell can also interact directly with B cells, providing them 
with signal that controls differentiation, expansion, and 
shaping of the antibody iso type that they secrete (Alberts 
et al., 2008).
Epitope has a high specificity in eliciting immune 
responses. Despite several potential advantages, the 
poor immunogenicity of epitope in the absence of 
adjuvant. And the adjuvant system suitable for human 
use has limited number approved by WHO. Many 
experimental adjuvants provide danger signals to DCs 
by engagement of one or more Toll-like receptors 
(TLRs) (Jackson et al., 2004). In this study we have 
designed a simple synthetic vaccine structure composed 
of a Th epitope from conserved M2e protein as a target 
epitope joined with P25 as T helper epitope, M2e 2-16-
K-P25 and branched structure M2e 2-10-K-(P25)M2e 
11-24 representing two Th epitopes from M2e 11-24 
and P25 and B epitope from M2e 2-10. The antigen 
was formulated with aluminium hydroxide gel in 
comparison with Freund’s complete adjuvant, targeting 
DC maturation, and induction antibody or cytotoxic T 
lymphocyte (CTL) responses.
Alhydrogel adjuvant was chosen in this study 
since this adjuvant has been approved by WHO and 
was used for long time without any adverse reactions.
To be more effective and enhance the solubility of 
peptide/epitopeafforded by placement of the lysine (K) 
molecule between the epitopes to create the linier and 
a branched structure, makes them highly attractive for 
the development of vaccines for human and animals. 
Dendritic cells (DCs) are instrumental in the initiation 
of the innate immune response because of their ability 
to take up antigens, to transport antigens to lymph 
nodes and to activate naıve antigen-specific T cells 
(adaptive immune response) (Alberts et al., 2008). 
Effective stimulation of T cells requires appropriate 
signals from DCs. The first signal is provided by 
processed antigenic peptides bound to MHC molecules 
recognized by the T cell receptors, and the second 
signal by the binding of co-stimulatory molecules to 
their ligands on T cells. Presentation of signal 1 in 
the absence of signal 2 leads to an important process 
in the maintenance of tolerance to self-molecules. 
A third signal is provided by cytokines and instructs 
the differentiation of T cells into TH1 or TH2 effector 
cells that can effectively deal with the inciting event, 
e.g. the infectious agents that induced the immune 
response. For example, the secretion of IL-12 directs 
the differentiation of CD4+ T cells to TH1 cells. 
Immature DCs localized in peripheral, non-lymphoid 
tissues are effective in the uptake of antigens through 
phagocytosis, receptor-mediated endocytosis, but 
do not effectively activate T cells because of the low 
expression of co-stimulatory molecules and cytokines. 
Maturation of DCs is characterized by increased 
expression of co-stimulatory molecules (signal 2) and 
secretion of cytokines (signal 3) resulting in mature 
DCs that efficiently activate antigen-specific naıve T 
cells. Aluminium salts are common adjuvants in human 
and veterinary vaccines because of their excellent safety 
record, proven ability to enhance the immune response 
to a variety of antigens, and low cost. The two main 
types of aluminium containing adjuvants are aluminium 
hydroxide, and aluminium phosphate adjuvant. The 
mechanism by which aluminium-containing adjuvants 
enhance the immune response is poorly understood. 
A commonly held view is that aluminium-adjuvanted 
vaccines form an antigen depot from which antigens 
are slowly released over time. Aluminium-containing 
adjuvants predo-minantly stimulate TH2 responses and 
this is independent of the cytokines IL-4, IL-6, and IL-
13. The TH2 response was diminished in the absence of 
IL-18 (Sokolovska et al., 2007)
We postulated that aluminium-containing adjuvants 
stimulate the immune response via a direct effect on 
DCs. Previous studies did not demonstrate an effect 
of aluminium-containing adjuvants on mouse DCs in 
vitro, but the adjuvants did induce, indirectly or directly, 
the expression of co-stimulatory molecules and DC 
markers on human monocytes and macrophages. The 
experiments indicate that aluminium adjuvants directly 
enhance the presentation of antigens to T cells (signal 
1), the expression of the co-stimulatory molecule CD86 
(signal 2) and the secretion of IL-1β and IL-18 (signal 3) 
by DCs. Neutralization of these cytokines and inhibition 
of their secretion demonstrated that they support TH2 
cell differentiation(Sokolovska et al., 2007).
It forms a proton-selective ion channel, which is 
activated at acidic pH and is a specific target of the anti-
influenza drugs amantadine and rimantadine. During 
virus entry, via receptor mediated endocytosis, M2 
transport protons across the virus membrane reducing 
the pH of the virion interior(De Fillete et al., 2008).
The M2 also plays an important role in virus 
morphogenesis and assembly. The M2 protein has 96 
amino acids, with three structural domains: an amino-
terminal extracellular domain (comprising 23 residues), 
a trans membrane domain (TM) (19 residues), and a 
cytoplasmic domain (54 residues) (Betakova, 2007).
The extracellular domain of M2 is important for its 
incorporation into virions. (M2e), which remain nearly 
invariable since the 1918 Spanish flu (Reid et al., 2002).
Mansyur, I., Soemitro, S., Subroto, T and Soedjanaatmadja, U.M.S. 37
MATERIALS AND METHODS
Mice; Female BALB/c mice (6–8 weeks of age) 
were obtained from an in house breeding colony at 
PT. Bio Farma, Bandung.  Mice were maintained in a 
conventional barrier facility at 21±2 °C and 50±20% 
relative humidity, and allowed free access to water 
and Lab Diet 5015 (Purina Mills Inc., Richmond, IN). 
Animal procedures were performed according to NIH 
guidelines for care and use of experimental animals 
and all experimental protocols involving mice were 
approved by Purdue Animal Care and Use Committee.
Immunization and bleeding protocols; Mice were 
grouped in three cages of 5 mice/cage, were inoculated 
twice on day 0 and 14 by subcutaneous route with 5, 10, 
and 20 nmol/dose peptides administered in alhydrogel 
compared to FCA/IFA adjuvant. Mice were bled through 
the retro-orbital plexus on day 10 to determine primary Ab 
response, and days 25 to determine secondary response.  
Reagents; The epitope choice was M2e2-24 as this 
component conserved since 1933 (Fiers et al., 2008). 
The Peptide/epitope was successfully synthesized in in 
Biochemistry Laboratory, Depart-ment of Chemistry, 
Faculty of Mathematics and Natural Sciences, Padja-
djaran University, using SPPHF moc/ btu method (Barlos 
and Gatos, 1999). The linear structure of epitope consist 
of B cell and T cell epitopes. Fitzmaurice et al., reported, 
branched structure of epitope has good immunogenicity 
and good antibody responses specific to M2e. We bought 
branched epitope from Genscript, USA. The linear 
structure has two epitopes, representing B cell from 
M2e2-16 and T cell epitope from P25 protein from canine 
distemper virus, (M2e 2-16-K-P25), and the branched 
structure has three target epitope representing B cell 
epitope from M2e-2-10, and two  T cell epitopes from 
M2e 11-24 and P25, (M2e 2-10-K-(P25) M2e 11-24). 
The antigens then formulated with aluminium hydroxide 
gel compared to FCA/IFA adjuvant (Sigma-Aldrich. St. 
Louis, MO). Alhydrogeland FCA/IFA adjuvants was uses 
as an adjuvant for the experimental vaccines. Aluminium 
hydroxide adjuvant were diluted with 0.9% NaCl and 
adjusted to pH 7.4 with 0.1M HCl and autoclaved at 121°C 
for 20 min. Vaccines were tested their immunogenicity and 
the potency to mature the dendritic cells for stimulating 
either CD8+ T cell or antibody-mediated immune 
responses. The maturity of dendritic cells indicated by the 
cytokines concentration, (IFN-γ, TFN-α, IL2 and IL4) and 
antibody titre was measured by ELISA test.
Determination of antibody titre; 96-well Immuno 
Platewere coatedovernight at 4°C with 100μL/well of 
the M2e peptide dilutedin PBS 1x.Plates were blocked 
with PBS/0.1% Tween-20/2% BSA (150μL/well)for 1h at 
37◦C,after washing three times with PBS/0.05% Tween-20, 
sera were added in 2-fold serial dilutions starting from 
1:50.The plates were incubated for 90 min at 37 °C, 
washed four timesand then incubated with 100 μL of goat 
peroxidase label anti mouse IgGfor 30 minutes at 37°C. 
After four washes, the presence of IgG was detectedwith 
100μL of tetrametylbenzidine. The reaction was stopped 
by adding 100μL of 0.18M H2SO4. The OD was read at450 
nm. Results are expressed as an antibody endpoint titre.
Determination of cytokines (IL2, IL4 and 
IFN-γ) concentration; IL 4 was determined by ELISA 
(Affymetrix e-Bioscience). Corning Costar 9018 (or 
Nunc Maxisorp®) ELISA plate was coated with 100 
μL/well of capture antibody in 1X Coating Buffer (dilute 
as noted on C of A, which is included with the reagent 
set). Plate was sealed and incubated overnight at 4°C. 
Wells were aspirate and wash 3 times with 250 μL/well 
Wash Buffer. Allowing time for soaking (~1 minute) 
during each wash step increases the effectiveness of the 
washes. Blot plate on absorbent paper to remove any 
residual buffer. Wells was block with 200 μL/well of 1x 
ELISA/ELISPOT diluent. Incubate at room temperature 
for 1 hour. Optional: Aspirate and wash at least once 
with Wash Buffer. Using 1x ELISA/ELISPOT Diluent, 
dilute standards as noted on the C of A to prepare the top 
concentration of the standard. Add 100 μL/well of top 
standard concentration to the appropriate wells. Perform 
2-fold serial dilutions of the top standards to make the 
standard curve for a total of 8 points. Add 100 μL/well of 
your samples to the appropriate wells. Seal the plate and 
incubate at room temperature for 2 hours (or overnight 
at 4°C) for maximal sensitivity. Wells was washed 
repeated for a total of 3-5 washes. Add 100 μl/well of 
detection antibody diluted in 1x ELISA/ELISPOT 
diluent* (dilute as noted on C of A). Seal the plate and 
incubate at room temperature for 1 hour. Aspirate/wash 
as in step 2. Repeat for a total of 3-5 washes. Add 100 
μL/well of Avidin-HRP diluted in 1x ELISA/ELISPOT 
Diluent. Seal the plate and incubate at room temperature 
for 30 minutes. Aspirate and wash as in step 2. In this 
wash step, soak wells in Wash Buffer* for 1 to 2 minutes 
prior to aspiration. Repeat for a total of 5-7 washes. Add 
100 μL/well of 1x TMB Solution to each well. Incubate 
plate at room temperature for 15 minutes. Add 50 μL 
of Stop Solution to each well. Read plate at 450 nm. If 
wavelength subtraction is available, subtract the values 
of 570 nm from those of 450 nm and analyse data. The 
procedures for IL-2 and IFN-μ determination is similar 




Figure 1. Antibody titre of BALB/C mice at day 10th after 
inoculation with formulated vaccines: inear peptide 
with alhydrogel (Lp-Al); linear peptide with CFA-and 
IFA (Lp-Fr); branched peptide with alhydrogel (Bp-
Al); branched peptide with CFA-and IFA (Bp-Fr); 
Alhydrogel (control Al,); and CFA-IFA (control Fr,); 
peptide consentrations  starting  with  (5 nmol/ dose,); 
(10 nmol/dose,); and (20 nmol/ dose, ).
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Antibody level of both linear and branched 
peptide are very low. This is the characteristic of a 
primary immune response occurring on an animal first 
exposure to an antigen. After some weeks, months or 
even years have elapsed, the animal immunized with 
the same antigen, it will usually produce a secondary 
immune response that differs from the primary 
respone, as shown in the figure 2  below.
Figure 2. Antibody titre of BALB/C mice at day 25 after 
second inoculation with formulated vaccines: 
linear peptide with alhydrogel (Lp-Al); linear 
peptide with CFA-and IFA (Lp-Fr); branched 
peptide with alhydrogel (Bp-Al); branched 
peptide with CFA-and IFA (Bp-Fr); Alhydrogel 
(control Al,); and CFA-IFA (control Fr,); peptide 
consentrations starting with (5 nmol/dose,); (10 
nmol/dose,); and (20 nmol/  dose,).
Figure 3. Antibody titre of BALB/C mice at day 40 after 
inoculation with formulated vaccines: linear 
peptide with alhydrogel (Lp-Al); linear peptide 
with CFA-and IFA (Lp-Fr); branched peptide 
with alhydrogel (Bp-Al); branched peptide with 
CFA-and IFA (Bp-Fr); Alhydrogel (control Al,); 
and CFA-IFA (control Fr,); peptide consentrations 
starting with (5 nmol/dose,); (10 nmol/dose,); 
and (20 nmol/dose,).
The results show that  antibody titer was increased 
significantly than shown in Figure 1. Linear peptide 
in FCA adjuvant is somewhat higher than linear 
peptide in alhydrogel. The same results also shown 
by branched peptide in FCA and alhydrogel, but the 
antibody level little bit lower than linear peptide.
Figure 4. Concentration of cytokines, IL-4 , and IL-2, in 
mice after inoculation subcutaneously with 20 
nmol/dose.
Cytokines concentration
These results indicate that aluminum-containing 
adjuvants activate DCs and influence their ability 
to direct TH1 and TH2 responses through the 
secretion of IL-2 and IL-4. In this study, the effects 
of aluminium hydroxide and FC adjuvants on antigen 
presentation, expression of costimulatory molecules 
and cytokines by mouse dendritic cells (DCs) and the 
ability of DCs to induce T helper cell differentiation 
were investigated. Aluminium hydroxide adjuvant 
had a significantly stronger effect than FC adjuvant. 
Aluminium-containing adjuvants also stimulated the 
release of IL-2 and IL-4.
These results indicate that aluminium-containing 
adjuvants activate DCs and influence their ability to 
direct TH1 and TH2 responses through the secretion 
of IL-2 and IL-4. Aluminium-containing adjuvants 
enhanced antigen presentation by DCs as indicated 
by increased IL-2 and  IL-4  secretion of naıve T cells. 
This indicates that aluminium-containing adjuvants 
enhance the efficiency of T cell activation by DCs. 
In summary, aluminium-containing adjuvants have 
a direct effect on DCs and enhance their ability to 
activate antigen-specific T cells. Taken together, 
these experiments demonstrate that aluminium-
containing adjuvants are not simple delivery vehicles 
for antigens, but directly activate DCs to effectively 
initiate immune responses and influence the ability of 
DCs to direct TH1 and TH2 responses.
CONCLUSIONS
From this study, demonstrating conserve epitope of 
Me2 2-16 when incorporated with P25 protein  from 
canine distemper virus (linear structure) in alhydrogel 
adjuvant has greater potential to produce  anti-M2e 
antibodies than in Freund adjuvant.  
Alhydrogeladjuvant  had a stronger effect than Freund 
adjuvant. Alhydrogel also stimulate the release of 
IL-2 and IL-4.
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